ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 1171 - 1185 of 5996 products
Connect Bio Reports Positive Data from Phase II Trial of Dermatitis Therapy
$5.00
Available
CBC China Life Science Infrastructure Fund Holds First Close with $500 Million
$5.00
Available
Clover Receives $38.9 Million CEPI Grant to Finish Development of COVID Vaccine
$5.00
Available
EdiGene Forms University Collaboration for RNA Edited Genetic Therapies
$5.00
Available
HebaBiz Approved to Start China Trial of Novel Hepatitis B Therapy
$5.00
Available
Shanghai AoHua Endoscope Raises $117 Million in IPO; Trades 71% Higher
$5.00
Available
Newsoara Expands In-Licensed Territory for BET Inhibitor to Asia
$5.00
Available
Ascletis Approved to Start China Trial of PD-L1 to Cure HIV-1
$5.00
Available
Everest Reports ADC Meets Endpoint for Triple-Negative Breast Cancer
$5.00
Available
Ignis Formed with $180 Million to Develop SK Bio's CNS Candidates in China
$5.00
Available
Gmax Starts China Phase I Trial of 2nd Gen Obesity Therapy
$5.00
Available
I-Mab Announces $315 Million Commercialization Deal for Growth Hormone
$5.00
Available
IASO Starts China Phase I/II Trial of CD19/CD22 CAR-T for Lymphoma
$5.00
Available
Zai Lab Signs Two In-Licensing Deals with $800 Million Total Value
$5.00
Available
Arbor, a US Gene Editing Company, Raises $215 Million Led by Singapore, Hong Kong, US Investors
$5.00
Available